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Abstract  
A 61-year-old woman, with a lifelong history of a giant congenital melanocytic nevus in the occipital region with 
secondary development of giant melanoma is presented. Surgical excision was performed, and the 
histopathological evaluation confirmed the diagnosis of Giant Malignant Melanoma (GMM) with a maximum 
tumour thickness of 16 mm. Nowadays, there is tremendous uncertainty regarding how giant congenital 
melanocytic nevi (GCMN) should be treated. The standard approach to patients with late onset giant congenital 
melanocytic nevi (GCMN is based on two main considerations: (1) obtain an acceptable cosmetic results with the 
purpose to decrease the psychosocial inconvenience to each patient, and (2) to attempt to minimise the risk of 
development of malignant transformation. Unfortunately complete surgical removal of the GCMN is usually difficult 
and very often impossible without subsequent functional or cosmetic mutilations. 
 
 
 
 
 
 
 
 
 
 
A 61-year-old woman, with a lifelong history of 
a giant congenital melanocytic nevus involving the 
occipital scalp, posterior neck and shoulders, and 
upper back, presented with a six-month history of an 
ulcerated tumour in the occipital region (Fig. 1a, 1b, 
1c). Magnetic resonance imaging confirmed the 
presence of an exophytic cutaneous tumour 
measuring 11.5 cm in greatest diameter as well as 
spinal stenosis in the area of C6 and C7. Abnormal 
laboratory studies included an increased C-reactive 
protein and an elevated serum S100 level (0.122 
mcg/l). Radiographic and ultrasonographic studies 
failed to show evidence of disease progression to 
lungs, lymph nodes or abdominal structures. A wide 
local excision was done, and the histopathology 
confirmed the diagnosis of malignant melanoma with 
a maximum thickness of 16 mm (Fig. 1d, 1e, 1f). 
Additional reexcision with 1,5cm safety margins was 
planned. Immunohistopathological stainings with 
HMB-45 (diffusely positive) and S-100 showed a 
strong positive reaction. The patient denied sentinel 
lymph node biopsy. Tumour was staged as IIB 
(T4aN0M0). A prophylactic interferon therapy (3 
MU/m
2
, 3 x weekly) was planned.  
Congenital melanocytic nevus (CMN) is 
defined, clinically, as a melanocytic lesion present at 
birth or which develops during infancy from 
preexistent melanocytes [1, 2]. The risk of developing 
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melanoma over a CMN is a nowadays very well 
established subject [1, 3]. It is believed that this risk is 
directly proportional to nevus size, varying from 2.6% 
to 4.9% for small and medium nevi and from 6% to 
20% for giant nevi [3]. For these reasons, surgical 
resection of giant congenital nevi is frequently 
recommended before puberty and when located in 
areas difficult to monitor [2]. Nowadays, there is 
tremendous uncertainty regarding how giant 
congenital melanocytic nevi (GCMN) should be 
treated. The standard approach to patients with 
GCMN is based on two main considerations: (1) 
obtain an acceptable cosmetic result to decrease the 
psychosocial inconvenience to the patient, and (2) 
attempt to minimise the risk of malignancy. 
 
Figure 1: 1a-1c, Clinical pictures of patient with Giant melanoma 
located on the basis of Giant Congenital Melanocytic Nevus; 1d-1f, 
Histopathological evaluation showing deep penetrating tumour cells 
 
To date, no absolute guidelines to treat these 
nevi have been given to our knowledge, and 
therefore, this subject remains one of the most 
controversial issues in dermatologic surgery and 
dermatologic oncology [4-6]. 
Complete removal of the GCMN is usually 
difficult and very often impossible without functional or 
cosmetic mutilation. Moreover, even after complete 
excision of GCMN down to the muscle fascia, the 
malignancy risk is not completely eradicated as 
malignant melanoma can occur at extracutaneous 
sites [7]. 
The most promising results of treating GCMN 
were originally reported by Moss in 1987 [8]. He 
performed curettage on GCMN during the first weeks 
of life to remove the superficially distributed nevus 
cells based on the fact that at that time, there seems 
to be a cleavage plane between the upper and the 
lower dermis. This technique offers the best 
alternative to classic surgery when the nevi are too 
large to perform complete excision, and it is a 
technique that is of benefit for these patient groups 
[9]. Treatment with targeted therapies, after 
phenotype characterization, should also be 
considered in selected cases [10, 11]. 
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